Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sugammadex Dose-Finding for Rocuronium Reversal
NCT00421148Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- May 2005
- Primary completion
- May 2006
- Modality
- Biodegradable Polymers, Small Molecules
01
Overview
Phase 3, randomised, single-blind trial of Sugammadex in neuromuscular blockade (NMB) (5 arms), sponsored by Merck & Co. Primary endpoint: Time From Start of Administration of Study Treatment to Recovery T4/T1 Ratio to 0.9. Started May 2005; status: completed.
02
Drugs
Sugammadex
03
Conditions
neuromuscular blockade (NMB)
Beyond the preview
Go deeper on NCT00421148.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00421148.